Related Experiment Video
Updated: Aug 6, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases
Daifei Shen1, Runji Chen2,3, Shu Ye2,3,4,5
1Research Center of Translational Medicine, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Research (Washington, D.C.)
|July 24, 2026
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to cardiovascular disease (CVD). Understanding this relationship can improve risk assessment and management for both conditions.
Area of Science:
- Hepatology and Cardiology
- Metabolic Syndrome Research
Background:
- Growing evidence links metabolic dysfunction-associated steatotic liver disease (MASLD) with cardiovascular disease (CVD).
- The conceptual shift from NAFLD to MASLD emphasizes a metabolism-centered approach to cardiovascular risk.
- The rising global prevalence of both MASLD and CVD necessitates a deeper understanding of their connection.
Purpose of the Study:
- To review epidemiological and clinical data on the association between MASLD and adverse cardiovascular outcomes.
- To explore the utility of liver-specific markers, like fibrosis indices, for cardiovascular risk stratification.
- To examine the shared metabolic pathways and the bidirectional liver-heart axis in MASLD-CVD.
Main Methods:
- Systematic review of epidemiological and clinical studies.
- Analysis of shared upstream metabolic mechanisms.
- Examination of molecular mediators in liver-heart interactions.
Main Results:
- MASLD is strongly associated with increased cardiovascular risk.
- Liver fibrosis indices may enhance cardiovascular risk stratification beyond traditional factors.
- Shared metabolic pathways and a bidirectional liver-heart axis mediate the interplay.
Conclusions:
- An integrated framework for MASLD and CVD is crucial for improved detection and management.
- Targeting shared mechanisms may offer dual hepatic and cardiovascular benefits.
- Multidisciplinary approaches are needed for effective patient care.
More Related Videos
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...